Effect of in-utero HIV exposure and antiretroviral treatment strategies on measles susceptibility and immunogenicity of measles vaccine

AIDS

Volumn 27, Issue 10, 2013, Pages 1583-1591

  Simani, Omphile E ^a   Adrian, Peter V ^a,b   Violari, Avy ^c   Kuwanda, Locadiah ^a,b   Otwombe, Kennedy ^c   Nunes, Marta C ^a,b   Cotton, Mark F ^d   Madhi, Shabir A ^a,b,e  

^a NATIONAL RESEARCH FOUNDATION   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; IMMUNOGLOBULIN G ANTIBODY; MEASLES VACCINE;

AGE DISTRIBUTION; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DISEASE PREDISPOSITION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INDIRECT ENZYME IMMUNOASSAY; INFANT; INFANT DISEASE; MAJOR CLINICAL STUDY; MALE; PERINATAL PERIOD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANTI-HIV AGENTS; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MEASLES; MEASLES VACCINE;

EID: 84879093306     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835fae26     Document Type: Article

References (37)

1. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, Hersh BS. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 2007; 369:191-200.
2. Measles vaccines. WHO position paper. Wkly Epid Rec 2009; 84:349-360.
3. Machaira M, Papaevangelou V. Current measles outbreaks: can we do better for infantsat risk? Pediat Infect Dis J 2012; 31:756-758.
4. National Institute for Communicable Diseases. Communicable Diseases Communique 2010. http://www.nicd.ac.za/assets/files/ NICD%20Communique%20October%202010.pdf [Accessed on 15 October 2012].
5. Moss WJ, Monze M, Ryon JJ, Quinn TC, Griffin DE, Cutts F. Prospective study of measles in hospitalized, human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia. Clin Infect Dis 2002; 35:189-196.
6. Leuridan E, Hens N, Hutse V, Ieven M, Aerts M, Van Damme P. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ 2010; 340:c1626.
7. Farquhar C, Nduati R, Haigwood N, Sutton W, Mbori-Ngacha D, Richardson B, et al. High maternal HIV-1 viral load during pregnancy is associated with reduced placental transfer of measles IgG antibody. J Acquir Immune Defic Syndr 2005; 40:494-497.
8. Caceres VM, Strebel PM, Sutter RW. Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin Infect Dis 2000; 31:110-119.
9. Kruczek AC, Cutland C, Madhi SA. Review of the effect of maternal HIV infection on measles-susceptibility during early infancy: implications for optimizing protection of the infant. HIV Therapy 2010; 4:471-482.
10. Scott S, Cumberland P, Shulman CE, Cousens S, Cohen BJ, Brown DW, et al. Neonatal measles immunity in rural Kenya: the influence of HIV and placental malaria infections on placental transfer of antibodies and levels of antibody in maternal and cord serum samples. J Infect Dis 2005; 191: 1854-1860.
11. Scott P, Moss WJ, Gilani Z, Low N. Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity. J Infect Dis 2011; 204 (Suppl 1): S164-S178.
12. HIV: panel on antiretroviral therapy and medical management of HIV-infected children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection 2011; pp. 1-268. http://aidsinfo.nih.gov/ContentFiles/ lvguidelines/PediatricGuidelines.pdf. [Accessed on 15 September 2012].
13. Aurpibul L, Puthanakit T, Siriaksorn S, Sirisanthana T, Sirisanthana V. Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapy. HIV Med 2006; 7:467-470.
14. Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007; 45:637-642.
15. Helfand RF, Moss WJ, Harpaz R, Scott S, Cutts F. Evaluating the impact of the HIV pandemic on measles control and elimination. Bull World Health Org 2005; 83:329-337.
16. Scott S, Mossong J, Moss WJ, Cutts FT, Cousens S. Predicted impact of the HIV-1 epidemic on measles in developing countries: results from a dynamic age-structured model. Int J Epidemiol 2008; 37:356-367.
17. Madhi SA, Adrian P, Cotton MF, McIntyre JA, Jean-Philippe P, Meadows S, et al. Effect of HIV infection status and antiretroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 2010; 202:355-361.
18. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233-2244.
19. Scott S, Moss WJ, Cousens S, Beeler JA, Audet SA, Mugala N, et al. The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants. Clin Infect Dis 2007; 45:1417-1424.
20. Lepage P, Dabis F, Msellati P, Hitimana DG, Stevens AM, Mukamabano B, et al. Safety and immunogenicity of high-dose Edmonston-Zagreb measles vaccine in children with HIV-1 infection. A cohort study in Kigali, Rwanda. Am J Dis Child 1992; 146:550-555.
21. Leuridan E, Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine 2007; 25: 6296-6304.
22. de Moraes-Pinto MI, Almeida AC, Kenj G, Filgueiras TE, Tobias W, Santos AM, et al. Placental transfer and maternally acquired neonatal IgG immunity in human immunodeficiency virus infection. J Infect Dis 1996; 173:1077-1084.
23. Thea DM, Steketee RW, Pliner V, Bornschlegel K, Brown T, Orloff S, et al. The effect of maternal viral load on the risk of perinatal transmission of HIV-1. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS 1997; 11:437-444.
24. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999; 341: 394-402.
25. John S, Lalitha G, George K, Joseph A. Serological response to early measles vaccination. J Trop Pediat 2004; 50:175-177.
26. Helfand RF, Witte D, Fowlkes A, Garcia P, Yang C, Fudzulani R, et al. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. J Infect Dis 2008; 198:1457-1465.
27. Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Iinfect Dis 2001; 184:817-826.
28. Martins CL, Garly ML, Bale C, Rodrigues A, Ravn H, Whittle HC, et al. Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. BMJ 2008; 337:a661.
29. Palma P, Romiti ML, Cancrini C, Pensieroso S, Montesano C, Bernardi S, et al. Delayed early antiretroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants. Vaccine 2008; 26:5196-5201.
30. Romiti ML, Cancrini C, Castelli-Gattinara G, Di Cesare S, Ciaffi P, Bernardi S, et al. Kinetics of the T-cell receptor CD4 and CD8 V beta repertoire in HIV-1 vertically infected infants early treated with HAART. AIDS 2001; 15:2075-2084.
31. Pensieroso S, Cagigi A, Palma P, Nilsson A, Capponi C, Freda E, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci 2009; 106:7939-7944.
32. Fowlkes A, Witte D, Beeler J, Audet S, Garcia P, Curns A, et al. Persistence of vaccine-induced measles antibody beyond age 12 months: a comparison of response to one and two doses of Edmonston-Zagreb measles vaccine among HIV-infected and uninfected children in Malawi. J Infect Dis 2011; 204 (Suppl 1): S149-S157.
33. Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling AC. Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. JAMA 2011; 305:576-584.
34. Ratnam S, Gadag V, West R, Burris J, Oates E, Stead F, et al. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol 1995; 33:811-815.
35. Cohen BJ, Doblas D, Andrews N. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination. Vaccine 2008; 26:6392-6397.
36. Nair N, Moss WJ, Scott S, Mugala N, Ndhlovu ZM, Lilo K, et al. HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection. J Infect Dis 2009; 200:1031-1038.
37. Chandwani S, Beeler J, Li H, Audet S, Smith B, Moye J, et al. Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225. J Infect Dis 2011; 204 (Suppl 1):S179-S189.